Given that rIL-RA was approved for the treatment of neonatal-onset multisystem inflammatory disease (NOMID) in 2012, rIL-RA is an ideal candidate drug targeting IL-1R1 to prevent FS generation as well as subsequent epileptogenesis, and translational studies in humans may be feasible. Here, PDLIM4 is linked to CINCA syndrome.